-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nizubaglustat in Niemann-Pick Disease Type C
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nizubaglustat in Niemann-Pick Disease Type C report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nizubaglustat in Niemann-Pick Disease Type C Drug Details: AZ-3102...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nizubaglustat in Tay-Sachs Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nizubaglustat in Tay-Sachs Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nizubaglustat in Tay-Sachs Disease Drug Details: AZ-3102 (nizubaglustat) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nizubaglustat in Sandhoff Disease (Jatzkewitz-Pilz Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nizubaglustat in Sandhoff Disease (Jatzkewitz-Pilz Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nizubaglustat in Sandhoff Disease (Jatzkewitz-Pilz Syndrome) Drug Details: AZ-3102 (nizubaglustat)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nizubaglustat in GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nizubaglustat in GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) Drug Details: AZ-3102 (nizubaglustat) is under development...
-
Product Insights
NewTay-Sachs Disease – Drugs In Development, 2024
Empower your strategies with our Tay-Sachs Disease – Drugs In Development, 2024 report and make more profitable business decisions. Tay-Sachs disease is a rare, inherited metabolic disease that mostly affects young children and involves progressive damage to and death of cells, particularly in the brain. It is caused by a mutation in the enzyme hexosaminidase A, which allows the harmful buildup of lipids (fatty materials such as oils and acids) in cells. Both parents must carry the mutated gene in order...
-
Product Insights
NewInherited Neurodegenerative Diseases – Drugs In Development, 2024
Empower your strategies with our Inherited Neurodegenerative Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Inherited neurodegenerative diseases are a group of disorders that affect the structure and function of neurons, leading to progressive loss of cognitive and motor abilities. Some of these diseases are caused by mutations in single genes, such as Huntington's disease, while others are influenced by multiple genetic and environmental factors, such as Alzheimer's disease and Parkinson's disease. The mechanisms of neuronal...